These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 24798935)

  • 41. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.
    Vergote IB; Garcia A; Micha J; Pippitt C; Bendell J; Spitz D; Reed N; Dark G; Fracasso PM; Ibrahim EN; Armenio VA; Duska L; Poole C; Gennigens C; Dirix LY; Leung AC; Zhao C; Soufi-Mahjoubi R; Rustin G
    J Clin Oncol; 2013 Nov; 31(32):4060-6. PubMed ID: 24081946
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
    Marth C; Vergote I; Scambia G; Oberaigner W; Clamp A; Berger R; Kurzeder C; Colombo N; Vuylsteke P; Lorusso D; Hall M; Renard V; Pignata S; Kristeleit R; Altintas S; Rustin G; Wenham RM; Mirza MR; Fong PC; Oza A; Monk BJ; Ma H; Vogl FD; Bach BA
    Eur J Cancer; 2017 Jan; 70():111-121. PubMed ID: 27914241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.
    Herzog TJ; Kutarska E; Bidzińsk M; Symanowski J; Nguyen B; Rangwala RA; Naumann RW
    Int J Gynecol Cancer; 2016 Nov; 26(9):1580-1585. PubMed ID: 27654255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
    Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
    J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
    ; Chou HH; Wang KL; Chen CA; Wei LH; Lai CH; Hsieh CY; Yang YC; Twu NF; Chang TC; Yen MS
    Gynecol Oncol; 2006 Jun; 101(3):423-8. PubMed ID: 16325239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
    Verschraegen CF; Czok S; Muller CY; Boyd L; Lee SJ; Rutledge T; Blank S; Pothuri B; Eberhardt S; Muggia F
    Ann Oncol; 2012 Dec; 23(12):3104-3110. PubMed ID: 22851407
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    Monk BJ; Brady MF; Aghajanian C; Lankes HA; Rizack T; Leach J; Fowler JM; Higgins R; Hanjani P; Morgan M; Edwards R; Bradley W; Kolevska T; Foukas P; Swisher EM; Anderson KS; Gottardo R; Bryan JK; Newkirk M; Manjarrez KL; Mannel RS; Hershberg RM; Coukos G
    Ann Oncol; 2017 May; 28(5):996-1004. PubMed ID: 28453702
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
    Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
    Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer.
    Tas F; Derin D; Guney N; Aydiner A; Topuz E
    Int J Clin Oncol; 2008 Aug; 13(4):330-4. PubMed ID: 18704633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of overall survival with 40 and 50mg/m
    Nakayama M; Kobayashi H; Takahara T; Nishimura Y; Fukushima K; Yoshizawa K
    Gynecol Oncol; 2016 Nov; 143(2):246-251. PubMed ID: 27612976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers.
    Ghisoni E; Maggiorotto F; Borella F; Mittica G; Genta S; Giannone G; Katsaros D; Sciarrillo A; Ferrero A; Sarotto I; Erriquez J; Di Renzo MF; Aglietta M; Valabrega G
    J Ovarian Res; 2019 Feb; 12(1):17. PubMed ID: 30760286
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
    Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
    Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.
    Poon D; Chowbay B; Cheung YB; Leong SS; Tan EH
    Cancer; 2005 Feb; 103(3):576-81. PubMed ID: 15612023
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
    Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study.
    Floquet A; Doussau A; Brouste V; Cany L; Dutin JP; Mathoulin-Pélissier S
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):61-8. PubMed ID: 24141374
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy.
    Nishikawa A; Hashimoto H; Takeda M; Kontani K; Miyatake T; Mimura M; Nagamatsu M; Yokoi T
    Eur J Gynaecol Oncol; 2016 Aug; 37(4):451-454. PubMed ID: 29894065
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
    Pignata S; Scambia G; Villanucci A; Naglieri E; Ibarbia MA; Brusa F; Bourgeois H; Sorio R; Casado A; Reichert D; Dopchie C; De Rivas B; de Sande LM
    Oncologist; 2021 Apr; 26(4):e658-e668. PubMed ID: 33289956
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.
    Motohashi T; Yabuno A; Michimae H; Ohishi T; Nonaka M; Takano M; Nishio S; Fujiwara H; Fujiwara K; Kondo E; Sugiyama T; Tabata T
    J Gynecol Oncol; 2021 Jan; 32(1):e9. PubMed ID: 33185050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.